SCORE Emerging Adult Cannabis Use & Stress (NCT05885542)
Sex Differences in the Interface Between Cannabis Use and Stress Among Emerging Adults
🩺 Plain-English Summary (8th-Grade Level)
The interface between cannabis use and stress is a particularly important focus for sex differences research in emerging adults. Given the dynamics at play in this critical stage when cannabis use is most prevalent, developmentally informed research is needed to guide tailored clinical interventions. This study will apply rigorous and innovative methods to elucidate sex differences in the nexus of cannabis use and stress among emerging adults with cannabis use disorder to guide the development of tailored treatments.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (7 items).
Location: Medical University of South Carolina — Charleston, South Carolina
Age range: 18 Years to 25 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Females who are pregnant, nursing, or planning to become pregnant during the study.
- Current severe substance use disorder other than cannabis
- Current medications or supplements with clinically significant interactions with cannabidiol (per Lexicomp, this list includes Blasting, Doxorubicin, Mavacamten, Pazopanib, Sirolimus, Topotecan, Vincristine, Afatinib, Berotraslstat, Cilostazol, Citalopram, Colchicine, Digoxin, Lefamulin, Relugolix, Relugolix+Estradiol+Norethindrone, Rimegepant, Tizanidine, Ubrogepant, and Venetoclax in the categories of "avoid combination" or "consider therapy modification")
- Current unstable psychiatric or medical disorder that would interfere with safety, compromise data integrity, or preclude reliable participation
- History of hypersensitivity to CBD, sesame, or sesame products
- Inability to comply with study procedures
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Medical University of South Carolina — Charleston, South Carolina
📞 Contact the Study Coordinator
Phone: (843) 792-0493
Email: bransonk@musc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cannabis Use Disorder
- SV2A Density Cannabis Use Disorder — New Haven, Connecticut
- Cannabidiol and Cannabis Concentrate Users — Aurora, Colorado
- RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative — New York, New York
- A Brief Intervention for Cannabis Use — Charleston, South Carolina
- Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder — Toronto, Ontario
Explore by condition: All Cannabis Use Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.